Search
Now showing items 1-7 of 7
Article
In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19
| Date Issued:
2021 | Copyright:
open access
Article
The clinically approved antiviral drug sofosbuvir inhibits Zika virus replication
| Date Issued:
2017 | Copyright:
open access
Article
Atazanavir, Alone or in Combination with Ritonavir, Inhibits SARS-CoV-2 Replication and Proinflammatory Cytokine Production
| Date Issued:
2020 | Copyright:
open access
Article
Sofosbuvir protects Zika virus-infected mice from mortality, preventing short- and long-term sequelae
| Date Issued:
2017 | Copyright:
open access
Article
Beyond Members of the Flaviviridae Family, Sofosbuvir Also Inhibits Chikungunya Virus Replication
| Date Issued:
2019 | Copyright:
open access
Article
Yellow fever virus is susceptible to sofosbuvir both in vitro and in vivo
| Date Issued:
2019 | Copyright:
open access
Article
Lipid droplets fuel SARS-CoV-2 replication and production of inflammatory mediators
| Date Issued:
2020 | Copyright:
open access